Back ground: There are no published clinical data in hemodialysis (HD) patients with mineral bone disorder (CKD-MBD) regarding the effect of sevelamer hydrochloride on the absorption of the oral calcitriol. Objectives: The aim of the present study was to determine the association of the sevelamer hydrochloride and serum 1-25(OH) 2 D concentration during oral calcitriol therapy. Methods: This was a before-and-after study in HD patients. Forty-six patients co-administered with phosphate-binder and calcitriol for CKD-MBD therapy took lanthanum carbonate (LC) and sevelamer hydrochloride (SH) for 4 weeks, respectively with calcitriol. The serum 1-25(OH) 2 D concentration was assessed after each period. Results: Serum 1-25(OH) 2 D concentration was significantly reduced with co-administration of SH compared to LH (mean, calcitriol with LC→SH: 19.9 pg/ml → 14.2 pg/ml, p 2 D concentrations after oral calcitriol administration compared to LH in HD patients. When we use SH as a phosphate binder with calcitriol for HD patients with CKD-MBD, we should consider the inhibitory effect of SH on oral calcitriol absorption.
Priè, D., Ureña Torres, P. and Friedlander, G. (2009) Latest Findings in Phosphate Homeostasis. Kidney International, 75, 882-889. http://dx.doi.org/10.1038/ki.2008.643
Mathew, S., Tustison, K.S., Sugatani, T., Cahudhary, L.R. and Hruska, K.A. (2008) The Mechanism of Phosphorus as a Cardiovascular Risk Factor in CKD. Journal of the American Society of Nephrology, 19, 1092-1105. http://dx.doi.org/10.1681/ASN.2007070760
Kestenbaum, B., Sampson, J.N., Rudser, K.D., Patterson, D.J., Young, S.L., et al. (2005) Serum Phosphate Levels and Mortality Risk among People with Chronic Kidney Disease. Journal of the American Society of Nephrology, 16, 520-552. http://dx.doi.org/10.1681/ASN.2004070602
Voormolen, N., Noordzij, M., Grootendorst, D.C., Beetz, I., Sijpkens, Y.W., van Manen, J.G., et al. (2007) High Plasma Phosphate as a Risk Factor for Decline in Renal Function and Mortality in Pre-Dialysis Patients. Nephrology Dialysis Transplantation, 22, 2909-2916. http://dx.doi.org/10.1093/ndt/gfm286
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney International, 76, S1-S130.
National Kidney Foundation (2003) KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. American Journal of Kidney Diseases, 42, S1-S201. http://dx.doi.org/10.1016/S0272-6386(03)00905-3
Fukagawa, M., Yokoyama, K., Koiwa, F., Taniguchi, M., Shoji, T., Kazama, J.J., et al. (2013) Clinical Practice Guideline for the Management of Chronic Kidney Disease-Mineral and Bone Disorder. Therapeutic Apheresis and Dialysis, 17, 247-288. http://dx.doi.org/10.1111/1744-9987.12058
Benini, O., D’Alessandro, C., Gianfaldoni, D. and Cupisti, A. (2011) Extra-Phosphate Load from Food Additives in Commonly Eaten Foods: A Real and Insidious Danger for Renal Patients. Journal of Renal Nutrition, 21, 303-308. http://dx.doi.org/10.1053/j.jrn.2010.06.021
Pohlmeier, R. and Vienken, J. (2001) Phosphate Removal and Hemodialysis Conditions. Kidney International. Supplement, 78, S190-S194. http://dx.doi.org/10.1046/j.1523-1755.2001.07812.x
Bushinsky, D.A. (2010) Contribution of Intestine, Bone, Kidney, and Dialysis to Extracellular Fluid Calcium Content. Clinical Journal of the American Society of Nephrology, 5, S12-S22. http://dx.doi.org/10.2215/CJN.05970809
Slatopolsky, E.A., Burke, S.K. and Dillon, M.A. (1999) RenaGel, a Nonabsorbed Calcium- and Aluminum-Free Phosphate Binder, Lowers Serum Phosphorus and Parathyroid Hormone. Kidney International, 55, 299-307. http://dx.doi.org/10.1046/j.1523-1755.1999.00240.x
Al-Baaj, F., Speake, M. and Hutchison, A.J. (2005) Control of Serum Phosphate by Oral Lanthanum Carbonate in Patients Undergoing Haemodialysis and Continuous Ambulatory Peritoneal Dialysis in a Short-Term, Placebo-Controlled Study. Nephrology Dialysis Transplantation, 20, 775-782. http://dx.doi.org/10.1093/ndt/gfh693
Suki, W.N., Zabaneh, R., Cangiano, J.L., Reed, J., Fisher, D., Garrett, L., et al. (2007) Effects of Sevelamer and Calcium-Based Phosphate Binders on Mortality in Hemodialysis Patients. Kidney International, 72, 1130-1137. http://dx.doi.org/10.1038/sj.ki.5002466
Wilson, R., Zhang, R.P., Smyth, M. and Pratt, R. (2009) Assessment of Survival in a 2-Year Comparative Study of Lanthanum Carbonate versus Standard Therapy. Current Medical Research and Opinion, 25, 3021-3028. http://dx.doi.org/10.1185/03007990903399398
Braunlin, W., Zhorov, E., Guo, A., Apruzzese, W., Xu, Q., Hook, P., et al. (2002) Bile Acid Binding to Sevelamer HCl. Kidney International, 62, 611-619. http://dx.doi.org/10.1046/j.1523-1755.2002.00459.x
US Prescribing Information Renagel (Sevelamer hydrochloride), Silver Spring, MD, USA, Center for Drug Evaluation and Research.
Pierce, D., Hossack, S., Poole, L., Robinson, A., Van Heusen, H., Martin, P. and Smyth, M. (2011) The Effect of Sevelamer Carbonate and Lanthanum Carbonate on the Pharmacokinetics of Oral Calcitriol. Nephrology Dialysis Transplantation, 26, 1615-1621. http://dx.doi.org/10.1093/ndt/gfq598
Brezina, B., Qunibi, W.Y. and Nolan, C.R. (2004) Acid Loading during Treatment with Sevelamer Hydrochloride: Mechanisms and Clinical Implications. Kidney International, 66, SS39-SS45. http://dx.doi.org/10.1111/j.1523-1755.2004.09007.x
Plone, M.A., Petersen, J.S., Rosenbaum, D.P. and Burke, S.K. (2002) Sevelamer, a Phosphate Binding Polymer, Is a Non-Absorbed Compound. Clinical Pharmacokinetics, 41, 517-523. http://dx.doi.org/10.2165/00003088-200241070-00005
Wrong, O. and Harland, C. (2007) Sevelamer and Other Anion-Exchange Resins in the Prevention and Treatment of Hyperphosphatemia in Chronic Renal Failure. Nephron Physiology, 107, 17-33.
Chertow, G.M., Burke, S.K. and Raggi, P. (2002) Sevelamer Attenuates the Progression of Coronary and Aortic Calcification in Hemodialysis Patients. Kidney International, 62, 245-252. http://dx.doi.org/10.1046/j.1523-1755.2002.00434.x
Shoji, T., Masakane, I., Watanabe, Y., Iseki, K., Tsubakihara, Y., et al. (2011) Elevated Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) Predicts Atherosclerotic Cardiovascular Events in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology, 6, 1112-1120. http://dx.doi.org/10.2215/CJN.09961110
Shigematsu, T., Lanthanum Carbonate Group (2008) Multicenter Prospective Randomized, Double-Blind Comparative Study between Lanthanum Carbonate and Calcium Carbonate as Phosphate Binders in Japanese Hemodialysis Patients with Hyperphosphatemia. Clinical Nephrology, 70, 404-410. http://dx.doi.org/10.5414/CNP70404
Levine, B.S. and Song, M. (1996) Pharmacokinetics and Efficacy of Pulse Oral versus Intravenous Calcitriol in Hemodialysis Patients. Journal of the American Society of Nephrology, 7, 488-496.
Wald, R., Tentori, F., Tighiouart, H., Zager, P.G. and Miskulin, D.C. (2007) Impact of the Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guidelines for Bone Metabolism and Disease in a Large Dialysis Network. American Journal of Kidney Diseases, 49, 257-266. http://dx.doi.org/10.1053/j.ajkd.2006.11.027
London, G.M., Guérin, A.P., Verbeke, F.H., Pannier, B., Boutouyrie, P., Marchias, S.J. and Mëtivier, F. (2007) Mineral Metabolism and Arterial Functions in End-Stage Renal Disease: Potential Role of 25-Hydroxyvitamin D Deficiency. Journal of the American Society of Nephrology, 18, 613-620. http://dx.doi.org/10.1681/ASN.2006060573
Wolf, M., Shah, A., Gutierrez, O., Ankers, E., Monroy, M., Tamez, H., et al. (2007) Vitamin D Levels and Early Mortality among Incident Hemodialysis Patients. Kidney International, 72, 1004-1013. http://dx.doi.org/10.1038/sj.ki.5002451